Microbiotix, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Microbiotix, Inc. - Product Pipeline Review - 2016', provides an overview of the Microbiotix, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Microbiotix, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Microbiotix, Inc. - The report provides overview of Microbiotix, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Microbiotix, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Microbiotix, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Microbiotix, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Microbiotix, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Microbiotix, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Microbiotix, Inc. Snapshot 7 Microbiotix, Inc. Overview 7 Key Information 7 Key Facts 7 Microbiotix, Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Microbiotix, Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Microbiotix, Inc. - Pipeline Products Glance 13 Microbiotix, Inc. - Clinical Stage Pipeline Products 13 Phase I Products/Combination Treatment Modalities 13 Microbiotix, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Microbiotix, Inc. - Drug Profiles 16 filociclovir 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 MBX-700 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 MBX-500 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 MBX-701 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 MBX-900 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecules to Inhibit 16S rRNA for Tuberculosis 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 KKL-35 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 MBX-2168 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 MBX-2319 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 MBX-2329 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 MBX-2359 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 MBX-2402 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 MBX-2546 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecule to Inhibit DNA Helicase for Infectious Diseases 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecules for Ebola Virus Infection 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecules for Fungal Infections 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecules for Gram-Negative Bacterial Infections 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit bNOS for MRSA Infections 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules to Inhibit BoNT/A LC for Botulism 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Small Molecules to Inhibit DNA Synthesis for Gram-Negative and Gram-Positive Bacterial Infections 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules to Inhibit NPC1 for Filovirus Infections 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecules to Inhibit PSAC for Malaria 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules to Inhibit the Fatty Acid Synthesis II for Pseudomonas Aeruginosa Infections 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Microbiotix, Inc. - Pipeline Analysis 45 Microbiotix, Inc. - Pipeline Products by Target 45 Microbiotix, Inc. - Pipeline Products by Route of Administration 46 Microbiotix, Inc. - Pipeline Products by Molecule Type 47 Microbiotix, Inc. - Pipeline Products by Mechanism of Action 48 Microbiotix, Inc. - Dormant Projects 49 Microbiotix, Inc. - Locations And Subsidiaries 50 Head Office 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables
Microbiotix, Inc., Key Information 7 Microbiotix, Inc., Key Facts 7 Microbiotix, Inc. - Pipeline by Indication, 2016 9 Microbiotix, Inc. - Pipeline by Stage of Development, 2016 11 Microbiotix, Inc. - Monotherapy Products in Pipeline, 2016 12 Microbiotix, Inc. - Phase I, 2016 13 Microbiotix, Inc. - Preclinical, 2016 14 Microbiotix, Inc. - Discovery, 2016 15 Microbiotix, Inc. - Pipeline by Target, 2016 45 Microbiotix, Inc. - Pipeline by Route of Administration, 2016 46 Microbiotix, Inc. - Pipeline by Molecule Type, 2016 47 Microbiotix, Inc. - Pipeline Products by Mechanism of Action, 2016 48 Microbiotix, Inc. - Dormant Developmental Projects,2016 49
List of Figures
Microbiotix, Inc. - Pipeline by Top 10 Indication, 2016 9 Microbiotix, Inc. - Pipeline by Stage of Development, 2016 11 Microbiotix, Inc. - Monotherapy Products in Pipeline, 2016 12 Microbiotix, Inc. - Pipeline by Top 10 Target, 2016 45 Microbiotix, Inc. - Pipeline by Route of Administration, 2016 46 Microbiotix, Inc. - Pipeline by Molecule Type, 2016 47 Microbiotix, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 48
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries sRead More...
Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the iRead More...
Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among otRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.